Q-omics provides the consensus-scored SNX18P1Y profile across patient tissues and cancer cell-line models. SNX18P1Y expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNX18P1Y is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, SNX18P1Y RNA expression shows 11,378 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where SNX18P1Y shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX18P1Y — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX18P1Y survival associations across molecular data types. SNX18P1Y RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX18P1Y RNA expression–survival associations across cancer types. High SNX18P1Y expression shows unfavorable associations in KIRC, UCS, ESCA, UVM and SKCM, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNX18P1Y RNA expression.
This table summarizes SNX18P1Y tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNX18P1Y. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX18P1Y shows higher tumor expression in KIRC, LUSC, LIHC and PRAD. The KIRC box plot shows higher SNX18P1Y RNA expression in tumor versus normal tissue (log2 FC = +0.090, t-test p = .004).
This table shows molecular features associated with SNX18P1Y in patient tissues and cancer cell lines. In patient samples, SNX18P1Y shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
